The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morimoto, H.
Right arrow Articles by Bonavida, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morimoto, H.
Right arrow Articles by Bonavida, B.

The Journal of Immunology, Vol 147, Issue 8 2609-2616, Copyright © 1991 by American Association of Immunologists

ARTICLES

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin- mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines

H Morimoto, JT Safrit and B Bonavida
Department of Microbiology and Immunology, UCLA School of Medicine, University of California 90024.

Recent studies have demonstrated that diphtheria toxin (DTX) also mediates target cell lysis, and the mechanism of cytotoxicity has many features similar to those of cytotoxicity mediated by TNF-alpha. Thus, we hypothesized that DTX and TNF-alpha, used in combination, may result in either additive or synergistic cytotoxic activity. This was examined on three human ovarian carcinoma cell lines chosen for their differing sensitivities to TNF-alpha and DTX, i.e., 222, which is sensitive to both TNF-alpha and DTX, 222TR, a TNF-alpha-resistant DTX-sensitive variant of 222, and SKOV-3, which is resistant to both DTX and TNF- alpha. The simultaneous use of DTX and TNF-alpha at suboptimal concentrations resulted in synergistic cytotoxic activity against all three lines tested, thus overcoming the TNF-alpha resistance of 222TR and the double resistance of SKOV-3. DNA fragmentation was observed in all three lines treated with DTX and TNF-alpha and occurred as early as 4 h after treatment. Cycloheximide, actinomycin D, or emetine, at concentrations causing greater than 90% protein synthesis inhibition, did not result in cytotoxicity alone or synergy with TNF-alpha, suggesting that synergy by DTX was not due to its ability to inhibit protein synthesis. The use of energy poisons and pH conditions that inhibit DTX-mediated cytotoxicity resulted in the abrogation of synergy. These findings show that the two cytotoxic agents TNF-alpha and DTX, when used at suboptimal concentrations, synergize in their cytotoxic activity against sensitive and resistant cell lines. Because the SKOV-3 cell line used here is also resistant to chemotherapeutic drugs, combination treatment with DTX and TNF-alpha may be beneficial in overcoming drug resistance.


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
H. Caldas, F. O. Jaynes, M. W. Boyer, S. Hammond, and R. A. Altura
Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy.
Mol. Cancer Ther., March 1, 2006; 5(3): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. D. Savellano, B. W. Pogue, P. J. Hoopes, E. S. Vitetta, and K. D. Paulsen
Multiepitope HER2 Targeting Enhances Photoimmunotherapy of HER2-Overexpressing Cancer Cells with Pyropheophorbide-a Immunoconjugates
Cancer Res., July 15, 2005; 65(14): 6371 - 6379.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tanaka, S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, A. Yamazaki, H. Mizushima, Y. Maehara, E. Mekada, et al.
Clinical Significance of Heparin-Binding Epidermal Growth Factor-Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4783 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Miyamoto, M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, H. Yagi, K. Sonoda, M. Kai, et al.
Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy
Cancer Res., August 15, 2004; 64(16): 5720 - 5727.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Senchenkov, T.-Y. Han, H. Wang, A. E. Frankel, T. J. Kottke, S. H. Kaufmann, and M. C. Cabot
Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF
Blood, September 15, 2001; 98(6): 1927 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Kumar, T. L. Whiteside, and U. Kasid
Identification of a Novel Tumor Necrosis Factor-alpha -inducible Gene, SCC-S2, Containing the Consensus Sequence of a Death Effector Domain of Fas-associated Death Domain-like Interleukin- 1beta -converting Enzyme-inhibitory Protein
J. Biol. Chem., January 28, 2000; 275(4): 2973 - 2978.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. S. Doi, M. W. Marino, T. Takahashi, T. Yoshida, T. Sakakura, L. J. Old, and Y. Obata
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality
PNAS, March 16, 1999; 96(6): 2994 - 2999.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.